Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study

Objective. To evaluate the longterm safety and efficacy of subcutaneous tocilizumab (TCZ-SC) as monotherapy in patients with rheumatoid arthritis (RA). Methods. Of 346 patients who received 24 weeks of double-blind treatment with either TCZ-SC monotherapy, 162 mg every 2 weeks (q2w); or intravenous TCZ (TCZ-IV) monotherapy, 8 mg/kg every 4 weeks; 319 patients continued to receive TCZ-SC q2w in the 84-week open-label extension (OLE) of the MUSASHI study (JAPICCTI-101117). Efficacy, safety, and immunogenicity were evaluated for all patients treated with TCZ during 108 weeks. Results. The proportions of patients who achieved American College of Rheumatology 20/50/70 responses, low disease activity [28-joint Disease Activity Score (DAS28) ≤ 3.2], or remission (DAS28 < 2.6) at Week 24 were maintained until Week 108. The incidences of adverse events and serious adverse events were 498.3 and 16.9 per 100 patient-years (PY), respectively. The overall safety of TCZ-SC monotherapy was similar to that of TCZ-IV monotherapy. Rates of injection site reactions (ISR) through 108 weeks remained similar to rates through 24 weeks. ISR were mild and did not cause any patient withdrawals. No serious hypersensitivity events (including anaphylactic reactions) occurred. Anti-TCZ antibodies were present in 2.1% of patients treated with TCZ-SC monotherapy. Conclusion. TCZ-SC monotherapy maintained a favorable safety profile and consistent efficacy throughout the 108-week study. Like TCZ-IV, TCZ-SC could provide an additional treatment option for patients with RA.

[1]  J. Pope,et al.  Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis , 2014, Arthritis care & research.

[2]  Y. Saeki,et al.  Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis , 2014, Arthritis care & research.

[3]  Désirée van der Heijde,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.

[4]  T. Tsuru,et al.  Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study) , 2013, Journal of clinical pharmacology.

[5]  S. Cessie,et al.  Association of High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent‐Onset Rheumatoid Arthritis Patients , 2013, Arthritis care & research.

[6]  J. Kremer,et al.  Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure , 2013, The Journal of Rheumatology.

[7]  I. Olivieri,et al.  Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine , 2013, Arthritis care & research.

[8]  Jeffrey R Curtis,et al.  2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis , 2012, Arthritis care & research.

[9]  D. Scott.  Biologics‐Based Therapy for the Treatment of Rheumatoid Arthritis , 2012, Clinical pharmacology and therapeutics.

[10]  T. Hirano,et al.  Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid Arthritis , 2012, Clinical medicine insights. Arthritis and musculoskeletal disorders.

[11]  Ricardo Blanco,et al.  Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. , 2011, Arthritis and rheumatism.

[12]  C. Wijbrandts,et al.  Body mass index and clinical response to infliximab in rheumatoid arthritis. , 2011, Arthritis and rheumatism.

[13]  K. Stubenrauch,et al.  Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. , 2010, Clinical therapeutics.

[14]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[15]  M. Genovese,et al.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.

[16]  N. Miyasaka,et al.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study , 2008, Annals of the rheumatic diseases.

[17]  N. Nishimoto,et al.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.

[18]  Kazuhiko Yamamoto,et al.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy , 2008, Modern rheumatology.

[19]  M. Genovese,et al.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. , 2008, Arthritis and rheumatism.

[20]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[21]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[22]  Frances Chilton,et al.  Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. , 2008, Musculoskeletal care.

[23]  D. M. van der Heijde,et al.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.

[24]  N. Arden,et al.  Patient preferences in choosing anti-TNF therapies , 2006 .

[25]  C. Edwards,et al.  Patient preferences in choosing anti-TNF therapies-R1. , 2006, Rheumatology.

[26]  D. Prakash,et al.  International Journal of Nanomedicine Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article , 2022 .